Induction of chemokine CCL3 by NF-κB reduces methylmercury toxicity in C17.2 mouse neural stem cells

Publication date: Available online 24 June 2019Source: Environmental Toxicology and PharmacologyAuthor(s): Tsutomu Takahashi, Min-Seok Kim, Miyuki Iwai-Shimada, Takayuki Hoshi, Masatake Fujimura, Takashi Toyama, Yasuyuki Fujiwara, Akira Naganuma, Gi-Wook HwangAbstractMethylmercury is an environmental pollutant that shows selective toxicity to the central nervous system. We previously reported that brain-specific expression of chemokine CCL3 increases in mice administered methylmercury. However, the relationship between CCL3 and methylmercury toxicity has not been elucidated. Here, we confirmed that induction of CCL3 expression occurs before pathological change by methylmercury treatment was observed in the mouse brain. This induction was also observed in C17.2 mouse neural stem cells before methylmercury-induced cytotoxicity. In addition, cells in which CCL3 was knocked-down showed higher methylmercury sensitivity than did control cells. Moreover, activation of transcription factor NF-κB was observed following methylmercury treatment, and methylmercury-mediated induction of CCL3 expression was partially suppressed by knockdown of p65, an NF-κB subunit. Our results suggest that NF-κB plays a role in the induction of methylmercury-mediated CCL3 expression and that this action may be a cellular response to methylmercury toxicity.
Source: Environmental Toxicology and Pharmacology - Category: Environmental Health Source Type: research

Related Links:

CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Publication date: Available online 10 October 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Thejus T. Jayakrishnan, Veli Bakalov, Zena Chahine, John Lister, Rodney E. Wegner, Santhosh Sadashiv
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
Publication date: 15 February 2021Source: Chemical Engineering Journal, Volume 406Author(s): Do Kyung Kim, Sanghyuk Lee, Minjeong Kim, Yunhui Jeong, Soonchul Lee
Source: Chemical Engineering Journal - Category: Chemistry Source Type: research
AbstractLike other malignancies, prostate tumors are thought to contain cancer stem-like cells (CSCs) that are responsible for growth, metastasis, and therapy resistance. ΔNp63 (also called p40) is a regulator of normal prostate stem/progenitor cell activities and a marker of normal basal epithelial cells. The levels of ΔNp63 are reduced in prostate adenocarcinomas, although there is also evidence that ΔNp63 is involved in CSC regulation and drives metastasis to t he bone. We studied metastatic deposits of prostate cancers with isoform-specific ΔNp63 and TAp63 antibodies. We identified p63-positive ...
Source: Virchows Archiv - Category: Pathology Source Type: research
It would dedicate $1.5 billion of its total to research and therapy for Alzheimer ’s Disease, Parkinson’s Disease, stroke, epilepsy and other brain and central nervous system conditions.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Publication date: Available online 8 October 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ram Vasudevan Nampoothiri, Shiyi Chen, Ivan Pasic, Zeyad Al-Shaibani, Wilson Lam, Fotios V. Michelis, Dennis Dong Hwan Kim, Auro Viswabandya, Armin Gerbitz, Jeffrey Howard Lipton, Rajat Kumar, Jonas Mattsson, Arjun Datt Law
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 8 October 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): M.M. Sulaiman, A.I. Ladu, A.M. Abba, A.A. Bukar
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 8 October 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Muhammad Bilal Abid, Saurabh Chhabra, Blake Buchan, Mary Beth Graham, Sameem Abedin, Bicky Thapa, Anita D'Souza, Ben George, Mehdi Hamadani
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
ConclusionSOS is relatively rare; therefore, a holistic approach to the patients ’ needs considering nursing role as essential may result in better care outcomes.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
It would dedicate $1.5 billion of its total to research and therapy for Alzheimer ’s Disease, Parkinson’s Disease, stroke, epilepsy and other brain and central nervous system conditions.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
More News: Brain | Drugs & Pharmacology | Environmental Health | Neurology | Stem Cell Therapy | Stem Cells | Toxicology